Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
116.32
-2.22 (-1.87%)
Mar 31, 2025, 10:00 AM EDT - Market open
Axsome Therapeutics Employees
Axsome Therapeutics had 683 employees as of December 31, 2024. The number of employees increased by 138 or 25.32% compared to the previous year.
Employees
683
Change (1Y)
138
Growth (1Y)
25.32%
Revenue / Employee
$564,704
Profits / Employee
-$420,521
Market Cap
5.67B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AXSM News
- 6 days ago - Axsome Therapeutics' ADHD drug meets main goal in late-stage study - Reuters
- 9 days ago - Axsome: The Alzheimer's Agitation Program For AXS-05 - Seeking Alpha
- 4 weeks ago - Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs - Benzinga
- 5 weeks ago - Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering - Seeking Alpha
- 5 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade - Seeking Alpha
- 6 weeks ago - Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' - Benzinga
- 2 months ago - Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewsWire